



Original Effective Date: 10/01/2018  
Current Effective Date: 01/31/2024  
Last P&T Approval/Version: 01/31/2024  
Next Review Due By: 01/2025  
Policy Number: C9017-A

## Mozobil (plerixafor)

### PRODUCTS AFFECTED

Mozobil (plerixafor), plerixafor

### COVERAGE POLICY

*Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.*

#### **Documentation Requirements:**

*Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.*

#### **DIAGNOSIS:**

Non-Hodgkin Lymphoma, Multiple Myeloma

#### **REQUIRED MEDICAL INFORMATION:**

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

All transplants require prior authorization from the Corporate Transplant Department. Must document transplant approval prior to approval of Mozobil.

#### **A. PERIPHERAL MOBILIZATION OF STEM CELLS:**

1. Documentation that member has been diagnosed with non-Hodgkin's lymphoma (NHL)

Drug and Biologic Coverage Criteria  
or multiple myeloma

AND

2. Documentation that plerixafor will be used in combination with a granulocyte colony stimulating factor (e.g., Neupogen)

AND

3. Prescriber attests to (or the clinical reviewer has found that) the member not having any FDA labeled contraindications that haven't been addressed by the prescriber within the documentation submitted for review [Contraindications to Mozobil (plerixafor) include: history of hypersensitivity to Mozobil, pregnancy, and patients with leukemia]

**CONTINUATION OF THERAPY:**

N/A

**DURATION OF APPROVAL:**

Initial authorization: ONE FILL, 4-day supply, Continuation of Therapy: N/A

For tandem HSCT requests, criteria must be met and approved per MCP-122 Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

**PRESCRIBER REQUIREMENTS:**

Prescribed by or in consultation with a board-certified hematologist/oncologist, or transplant specialist

**AGE RESTRICTIONS:**

18 years of age and older

**QUANTITY:**

≤83 kg: 20mg fixed dose or 0.24 mg/kg

>83 kg: 0.24 mg/kg

Maximum daily dose 40 mg

**Maximum Quantity Limits – Mozobil 24 mg vial: 8 vials per 4 days**

**PLACE OF ADMINISTRATION:**

The recommendation is that injectable medications in this policy will be for pharmacy or medical benefit coverage and the subcutaneous injectable products administered in a place of service that is a non-hospital facility-based location.

**DRUG INFORMATION**

**ROUTE OF ADMINISTRATION:**

Subcutaneous Injection

**DRUG CLASS:**

CXCR4 Receptor Antagonist

**FDA-APPROVED USES:**

Mozobil (plerixafor) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

**COMPENDIAL APPROVED OFF-LABELED USES:**

None

**APPENDIX****APPENDIX:**

None

**BACKGROUND AND OTHER CONSIDERATIONS****BACKGROUND:**

The National Comprehensive Cancer Network Guidelines (NCCN Guidelines):  
The guidelines recommend that high dose therapy with stem cell support is a critical component in the treatment plan for eligible newly diagnosed MM patients and that all types of stem-cell transplantations are appropriate in different clinical settings. Autologous HSCT results in high response rates and remains the standard of care following primary therapy for eligible patients and is an option for treatment of primary progressive or refractory disease post induction treatment. A tandem transplant can be considered for all patients who are candidates for stem cell transplant and is an option for patients who do not achieve at least a very good partial response after the first autologous stem cell transplant. Allogeneic HSCT may be an accepted option in the setting of a clinical trial in patients responding to primary therapy or primary progressive disease, or as salvage therapy in patients with progressive disease following an initial autologous HSCT.

**CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:**

All other uses of Mozobil (plerixafor) are considered experimental/investigational and therefore, will follow Molina's Off-Label policy. Contraindications to Mozobil (plerixafor) include: history of hypersensitivity to Mozobil, pregnancy, and patients with leukemia.

**OTHER SPECIAL CONSIDERATIONS:**

None

**CODING/BILLING INFORMATION**

*Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement*

<b>HCPCS CODE</b>	<b>DESCRIPTION</b>
J2562	Injection, plerixafor,1mg

**AVAILABLE DOSAGE FORMS:**

Mozobil SOLN 24MG/1.2ML single-dose vial  
Plerixafor SOLN 24MG/1.2ML single-dose vial

**REFERENCES**

1. Mozobil (plerixafor) [prescribing information]. Cambridge, MA: Genzyme Corporation; September 2023.
2. DiPersio J, Stadtmauer EA, Nademanee AP, et al. A Phase III, Multicenter, Randomized, Double Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs.G- CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation. *Blood*. 2007; 110: 445.
3. Dipersio JF, Micallef I, Stiff PJ, et al. A Phase III, Multicenter, Randomized, Double Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+ G-CSF vs. Placebo+G- CSF in NonHodgkin's Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation. *Blood*.

Drug and Biologic Coverage Criteria  
2007; 110: 601.

4. National Comprehensive Cancer Network. 2023. Hematopoietic Cell Transplantation (HCT) (Version 3.2023). [online] Available at: < [hct.pdf \(nccn.org\)](https://www.nccn.org/pdf/hct.pdf) > [Accessed 8 December 2023].

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: Required Medical Information Available Dosage Forms References	Q1 2024
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Duration of Approval Prescriber Requirements Quantity FDA-Approved Uses Contraindications/Exclusions/Discontinuation	Q1 2023
Q2 2022 Established tracking in new format	Historical changes on file